Argenica Therapeutics Limited (ASX:AGN)

Australia · Delayed Price · Currency is AUD

0.1400

-0.0050 (-3.45%)

Jul 15, 2026, 12:00 PM AEST

Argenica Therapeutics Earnings Call Transcripts

Fiscal Year 2026

Investor update
All FDA-requested assays for xaranetide are complete, enabling IND submission for a phase II-B trial focused on moderate to severe stroke patients. Interim analysis at 50% enrollment will be a key milestone, with strong financial planning and non-dilutive funding supporting both stroke and TBI programs.

Read full transcript →

Slides